1 Introduction
==============

Most treatable risk factors are common in cerebrovascular and coronary atherosclerosis \[[@b1-med-2015-0060], [@b2-med-2015-0060]\]. The main risk factors include hypertension, diabetes mellitus, dyslipidaemia and smoking. The risk of stroke increases with a combination of these factors \[[@b3-med-2015-0060]\]. Diabetes mellitus significantly increases the risk of an ischaemic cerebrovascular accident \[[@b4-med-2015-0060]--[@b6-med-2015-0060]\]. Intensive control of glycaemia after stroke, however, does not improve the prognosis; in fact, it increases the risk of hypoglycaemia. The "United Kingdom Glucose Insulin in Stroke" study even demonstrated an insignificantly higher mortality rate in the group with intensive glycaemia control \[[@b7-med-2015-0060]\]. An increased cholesterol level is a significant risk factor for stroke \[[@b8-med-2015-0060]\], and a similar effect is associated with triglyceride levels \[[@b9-med-2015-0060]\]. Various cholesterol-lowering medications influence the risk of cerebrovascular events to varying degrees \[[@b10-med-2015-0060]\]. Statins reduce the risk of stroke \[[@b11-med-2015-0060]\], but when acutely administered in high doses, they can positively influence its consequences. Apart from reducing cholesterol levels, statins also increase the level of endothelial nitric oxide synthetase, which controls the tension of the endothelium and laminar flow. They also increase the expression of endogenous tissue-type plasminogen activator, have antithrombotic effects, improve collateral circulation and reduce inflammatory mediators \[[@b12-med-2015-0060]\].

2 Materials and methods
=======================

2.1 Participants
----------------

In a retrospective study of 3,290 patients who were hospitalised in the Stroke Unit at the University Hospital in Hradec Králové (UHHK), we monitored the relative frequency of use over time of six anti-diabetic drugs, two types of statins, 28 antihypertensives and four types of antiplatelet drugs ([Table 1](#t1-med-2015-0060){ref-type="table"}) from 2005 to 2012. All patients were admitted for an acute cerebrovascular event. The drugs used as part of long-term medication taken by the patients before the admission to the Stroke Unit were evaluated. The sample included 46.1 % of women and 53.9 % of men. The mean age was 68.7 ± 14.4 years.

The research related to human use has been complied with all the relevant national regulations, institutional policies and in accordance the tenets of the Helsinki Declaration, and has been approved by the authors' institutional review board or equivalent committee.

Informed consent has been obtained from all individuals included in this study.

2.2 Statistical methods
-----------------------

Linear regression was used to assess the significance of the observed trends in the use of individual drugs. The values that were considered significant at the 5% significance level, indicating an increasing or decreasing trend in the relative frequencies of administered substances, are discussed, and possible causes are explored.

3 Results
=========

A statistically significant decrease in the relative frequency of use occurred for antiplatelet medications including dipyridamole, clopidogrel and ticlopidine ([Fig. 1](#f1-med-2015-0060){ref-type="fig"}, [Tab. 1](#t1-med-2015-0060){ref-type="table"}). In some patients, these drugs were prescribed for secondary prevention of ischemic heart disease (IHD) and thus they also provided primary prevention of stroke, while in other patients, antiplatelets were prescribed mainly for primary or secondary stroke prevention. An increase in metformin use and a decrease in insulin use occurred among the anti-diabetic drugs ([Fig. 2](#f2-med-2015-0060){ref-type="fig"}, [Tab. 1](#t1-med-2015-0060){ref-type="table"}). Antidiabetics were prescribed to treat diabetes as a stroke risk factor. Therefore, they are to be considered as primary prevention modality. Among the antihypertensives, ramipril was the only drug with a significant increase, whereas a decline occurred in the use of diuretic drugs including amiloride and hydrochlorothiazide, calcium channel blockers including amlodipine and diltiazem, and ACE inhibitors including enalapril and the alpha-blocker terazosin ([Fig. 3](#f3-med-2015-0060){ref-type="fig"}, [Tab. 1](#t1-med-2015-0060){ref-type="table"}). Similar to antidiabetics, antihypertensives were prescribed for primary stroke prevention. In the group of drugs reducing cholesterol levels, the frequency of atorvastatin administration increased at the expense of simvastatin ([Fig. 4](#f4-med-2015-0060){ref-type="fig"}, [Tab. 1](#t1-med-2015-0060){ref-type="table"}). Cholesterol-lowering agents as well as ***antidiabetics*** were prescribed for primary prevention of stroke and IHD in patients in whom dietary measures failed.

4 Discussion
============

Diabetes mellitus is a risk factor for recurrent, mainly lacunar strokes \[[@b13-med-2015-0060]\]. Despite the positive effects of good compensation of diabetes on reduction of microvascular complications, clinical studies with aggressive reduction of glycaemia did not prove such approach successful \[[@b14-med-2015-0060]\]. On the other hand, aggressive reduction of blood pressure and low-density lipoprotein (LDL) cholesterol levels in diabetics leads to important reduction in risk of cerebrovascular events \[[@b15-med-2015-0060], [@b16-med-2015-0060]\]. The significant drop in the number of diabetic patients treated with insulin agrees with the finding that insulin, compared to oral anti-diabetic drugs, has no positive effects on the width of the carotid wall or on vascular function \[[@b17-med-2015-0060]\]. And the arterial wall thickness of the carotid artery, particularly the intima-media thickness, is an important predictive parameter for ischemic stroke and it can be reliably measured by ultrasound \[[@b18-med-2015-0060]\]. The anti-sclerotic effect of metformin has been demonstrated \[[@b19-med-2015-0060]\] and is more significant than the effect of gliclazide or glibenclamide \[[@b20-med-2015-0060]\], which explains the significant increase in patients treated with metformin ([Fig. 2](#f2-med-2015-0060){ref-type="fig"}, [Tab. 1](#t1-med-2015-0060){ref-type="table"}). Furthermore, therapy with metformin is associated with lower mortality and less cardiovascular risks than therapy with glimepiride or glibenclamide \[[@b21-med-2015-0060]\]. Metformin is an activator of adenosine 5′-monophosphate-activated protein kinase (AMPK), and if it is administered in experimental cerebral ischemia, it increases the extent of injury. However, when it was administered chronically before stroke, it had a neuroprotective effect in both experiments and clinical studies \[[@b22-med-2015-0060]\]. Metformin has been found to support neurogenesis and improve spatial memory \[[@b23-med-2015-0060], [@b24-med-2015-0060]\]. An insignificant decrease in patients treated with glibenclamide was observed, which corresponds with the finding that glibenclamide is associated with a greater risk of complications, such as arrhythmia and ischaemic complications, than glimepiride and gliclazide \[[@b25-med-2015-0060]\].

Metaanalyses provided evidence that increased LDL levels are associated with increased risk of stroke. Reduction of LDL levels is the main aim of dyslipidemia management after stroke. Each 1 mmol/L reduction of LDL levels is associated with risk reduction of 21 % \[[@b26-med-2015-0060]\]. In the case of hydroxymethylglutaryl coenzyme A reductase inhibitors (i.e., statins), significantly less negative effects of stroke were demonstrated with atorvastatin than with simvastatin \[[@b27-med-2015-0060]\]. In the IDEAL study, major cardiovascular events (myocardial infarction and ischaemic cerebrovascular accidents \[[@b28-med-2015-0060]\]) occurred significantly less often in the group given atorvastatin. Atorvastatin, in comparison with simvastatin, also offers better control of hypercholesterolemia \[[@b29-med-2015-0060]\]. This fact corresponds with the demonstrated trend toward decreasing the use of simvastatin and the simultaneous increase in the use of atorvastatin for the treatment of hypercholesterolemia in the current group of patients ([Fig. 4](#f4-med-2015-0060){ref-type="fig"}, [Tab. 1](#t1-med-2015-0060){ref-type="table"}).

Studies show a linear correlation between stroke risk reduction and blood pressure. A prospective study showed that every 10 mm Hg reduction of blood pressure in primary prevention reduces the risk of stroke by one third \[[@b30-med-2015-0060]\]. In addition, patients with pre-existing hypertension have 25% higher risk of stroke than patients without hypertension \[[@b31-med-2015-0060], [@b32-med-2015-0060]\]. In acute phase of cerebrovascular accident numerous prognostic scoring systems are used to predict clinical outcome -- systolic or mean arterial blood pressure on admission is typically a very important component of these systems \[[@b33-med-2015-0060]\]. Antihypertensives comprise a large group of monitored drugs as well as the group whereby the greatest number of new products occurs. A significant increase in ramipril administration was observed ([Fig. 3](#f3-med-2015-0060){ref-type="fig"}, [Tab. 1](#t1-med-2015-0060){ref-type="table"}). In the HOPE study, this drug decreased the relative risk of stroke by 32% and the risk of death following CVA by 61% \[[@b34-med-2015-0060]\]. A significant drop in use was observed for diuretics such as hydrochlorothiazide and amiloride. Amiloride is associated with the risk of hyperkalaemia and acidosis. Although it has preventive effects against stroke in animal models, human studies have not shown evidence to support this effect \[[@b35-med-2015-0060]\]. Although hydrochlorothiazide is the most widely used antihypertensive in the world, it has demonstrated lower efficacy than most other antihypertensive drugs, and it is not recommended as a first-choice drug. Furthermore, there is no evidence that hydrochlorothiazide reduces the risk of stroke \[[@b36-med-2015-0060]\]. However, a significant decrease in the administration of amlodipine (a calcium channel blocker) was observed, even though according to meta-analyses, it provides greater protection against stroke than the other antihypertensive medications that were monitored \[[@b37-med-2015-0060]\]. Similarly, diltiazem (a calcium channel blocker) decreases the risk of stroke by 25% in comparison with diuretics and betablockers; despite this, a significant decrease in its administration was observed \[[@b38-med-2015-0060]\]. In the case of the ACE inhibitor enalapril, there is no evidence from human studies available to show that it has a protective effect against stroke. Regarding terazosin administered to patients with hypertension with benign prostate hyperplasia, the reason for the decrease appears to be pharmaco-economic \[[@b39-med-2015-0060]\]. The greater number of antihypertensives that had a significant declining trend in use for therapy among patients with stroke, compared to other antihypertensives, is due to the small increase in the administration of a large number of various types of new antihypertensives ([Fig. 3](#f3-med-2015-0060){ref-type="fig"}, [Tab. 1](#t1-med-2015-0060){ref-type="table"}). It is still being discussed, whether specific groups of antihypertensives are more effective in primary and secondary prevention of stroke than others. The blood pressure reduction itself is probably the main mechanism of action. Current recommendations do not prefer any specific group of antihypertensives. The choice of antihypertensives in some subgroups of patients with co-morbidities is defined by concurrent treatment of the co-morbidity \[[@b40-med-2015-0060]\].

The significant drop in administration of all groups of antiplatelet drugs, with the exception of acetylsalicylic acid, was clearly caused by a recommendation by the committee of the cerebrovascular section of the Czech Neurological Society, which prefers a 100 -- 150 mg dose of acetylsalicylic acid as the drug of first choice ([Fig. 1](#f1-med-2015-0060){ref-type="fig"}, [Tab. 1](#t1-med-2015-0060){ref-type="table"}).

No significant trends were observed in the use of the anticoagulants.

This work was not supported by any grant or research plan and there are no liabilities that could lead to a conflict of interests.

**Conflict of interests:** All the authors have no conflicts of interest regarding this submission.

![The predominant position of acetylsalicylic acid (ASA) among antiplatelet drugs is connected with a significant decrease in use of all other antiplatelet agents. This trend was caused by changes in guidelines for an antiplatelet therapy of cerebrovascular diseases at the beginning of monitored period.](med-2015-0060f1){#f1-med-2015-0060}

![Antidiabetics were associated with a decrease in insulin significant at the 1% significance level, whereas an increase in metformin use was significant at the 5% significance level.](med-2015-0060f2){#f2-med-2015-0060}

![In the treatment of high blood pressure we observed a decrease in use of enalapril and an increase in use of ramipril in a class of ACE inhibitors. In the class of ACE inhibitors in total there was no statistically significant trend. In class of angiotensin II receptor antagonists (losartan a telmisartan) we did not detect any changes in use of individual drugs nor in total. The share of calcium channel blockers was decreasing in monitored period, most distinctly in case of amlodipine and diltiazem. The use of alpha blockers was decreased in total, in this class there is a statistically significant decrease of terazosin. We observed no significant changes in the group of beta blockers as well as in the group of centrally acting antihypertensives. In class of diuretics a decrease of amiloride and hydrochlorothiazide occurred, the share of this group was decreased in total.](med-2015-0060f3){#f3-med-2015-0060}

![An increase in atorvastatin use (at the 5% significance level) and a decrease in simvastatin use (at the 1% significance level) occurred in the treatment of hypercholesterolemia.](med-2015-0060f4){#f4-med-2015-0060}

###### 

Drugs monitored in this study that had a statistically significant increase or decrease in use between 2005 and 2012

  -------------------------------------- ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Anti-diabetic drugs                    glibenclamide, gliclazide, glimepiride, insulin ▼[\*\*](#tfn3-med-2015-0060){ref-type="table-fn"}, metformin ▲[\*](#tfn2-med-2015-0060){ref-type="table-fn"}, repaglinide
                                         
  Statins                                atorvastatin ▲[\*](#tfn2-med-2015-0060){ref-type="table-fn"}, simvastatin ▼[\*\*](#tfn3-med-2015-0060){ref-type="table-fn"}
                                         
  Antihypertensives                      
   ACE inhibitors                        captopril, cilazapril, enalapril ▼[\*\*](#tfn3-med-2015-0060){ref-type="table-fn"}, perindopril, ramipril ▲[\*](#tfn2-med-2015-0060){ref-type="table-fn"}, trandolapril
   Angiotensin II receptor antagonists   losartan, telmisartan
   Calcium channel blockers              amlodipine ▼[\*\*](#tfn3-med-2015-0060){ref-type="table-fn"}, diltiazem ▼[\*](#tfn2-med-2015-0060){ref-type="table-fn"}, felodipine, nifedipine, nitrendipine, verapamil
   Alpha blockers                        doxazosin, terazosin ▼[\*](#tfn2-med-2015-0060){ref-type="table-fn"}, urapidil
   Beta blockers                         acebutolol, atenolol, betaxolol, metoprolol
   Diuretics                             amiloride ▼[\*\*](#tfn3-med-2015-0060){ref-type="table-fn"}, furosemide, hydrochlorothiazide ▼[\*\*](#tfn3-med-2015-0060){ref-type="table-fn"}, indapamide, spironolactone
   Centrally acting                      methyldopa, rilmenidine
                                         
  Antiplatelet drugs                     aspirin, aspirin + dipyridamol ▼[\*\*](#tfn3-med-2015-0060){ref-type="table-fn"}, clopidogrel ▼[\*\*](#tfn3-med-2015-0060){ref-type="table-fn"}, ticlopidin ▼[\*\*](#tfn3-med-2015-0060){ref-type="table-fn"}
  -------------------------------------- ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

▲ indicates an increasing trend, and ▼ indicates a decreasing trend.

5% significance level and

1% significance level.
